Auteurs
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Auteurs » - entrée « Akinari Mizokami »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Akimitsu Hiraki < Akinari Mizokami < Akinari Sekine  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
000359 (2019) Ryuki Sakaguchi [Japon] ; Keita Fujikawa [Japon] ; Momoko Okamoto [Japon] ; Emi Matsuo [Japon] ; Kohei Matsumoto [Japon] ; Tomohisa Uchida [Japon] ; Kawashiri Shin-Ya [Japon] ; Masahiro Nakashima [Japon] ; Akinari Mizokami [Japon] ; Atsushi Kawakami [Japon]Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder.
000464 (2019) Tomohisa Uchida ; Momoko Okamoto ; Keita Fujikawa ; Daisuke Yoshikawa ; Akinari Mizokami ; Tomo Mihara ; Akira Kondo ; Kazuo Ohba ; Kazuhiro Kurohama ; Masahiro Nakashima ; Ichiro Sekine ; Shigeki Nakamura [Japon] ; Yoshitsugu Miyazaki [Japon] ; Atsushi Kawakami [Japon]Gastric mucormycosis complicated by a gastropleural fistula: A case report and review of the literature.
000B99 (2017) Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Toshihiko Hidaka [Japon] ; Fumikazu Sakai [Japon] ; Mizue Hasegawa ; Yayoi Hashiba [Japon] ; Eiichi Suematsu [Japon] ; Hiroshi Tatsukawa [Japon] ; Akinari Mizokami [Japon] ; Shigeru Yoshizawa [Japon] ; Naoyuki Hirakata [Japon] ; Yukitaka Ueki [Japon]Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.
000E52 (2016) Naoki Iwamoto [Japon] ; Shoichi Fukui [Japon] ; Masataka Umeda [Japon] ; Ayako Nishino [Japon] ; Yoshikazu Nakashima [Japon] ; Takahisa Suzuki [Japon] ; Yoshiro Horai [Japon] ; Fumiaki Nonaka [Japon] ; Akitomo Okada [Japon] ; Tomohiro Koga [Japon] ; Shin-Ya Kawashiri [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki ; Kunihiro Ichinose [Japon] ; Yasuko Hirai [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Kaoru Terada ; Munetoshi Nakashima [Japon] ; Akinari Mizokami [Japon] ; Tomoki Origuchi [Japon] ; Katsumi Eguchi [Japon] ; Yukitaka Ueki ; Atsushi Kawakami [Japon]Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
001900 (2011) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Satoshi Yamasaki ; Hideki Nakamura ; Tomoki Origuchi ; Yukitaka Ueki ; Kiyoshi Migita ; Akinari Mizokami ; Kiyoshi Aoyagi ; Katsumi EguchiIn rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
001920 (2011) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Satoshi Yamasaki ; Hideki Nakamura ; Yukitaka Ueki ; Kiyoshi Migita ; Akinari Mizokami ; Tomoki Origuchi ; Kiyoshi Aoyagi ; Katsumi EguchiDisease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
001D20 (????) Shin-Ya Kawashiri [Japon] ; Ayako Nishino [Japon] ; Takahisa Suzuki [Japon] ; Yoshikazu Nakashima [Japon] ; Yoshiro Horai [Japon] ; Yukitaka Ueki [Japon] ; Toshiyuki Aramaki [Japon] ; Keita Fujikawa [Japon] ; Munetoshi Nakashima [Japon] ; Akitomo Okada [Japon] ; Kiyoshi Migita [Japon] ; Akinari Mizokami [Japon] ; Naoki Matsuoka [Japon] ; Masanobu Mine [Japon] ; Soko Sakito [Japon] ; Naoki Iwamoto [Japon] ; Kunihiro Ichinose [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Kiyoshi Aoyagi [Japon] ; Katsumi Eguchi [Japon] ; Atsushi Kawakami [Japon]Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i -k "Akinari Mizokami" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Author.i  \
                -Sk "Akinari Mizokami" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Akinari Mizokami
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021